Skip to main content
. 2020 Mar 2;52(3):409–422. doi: 10.1038/s12276-020-0390-4

Fig. 4. PROM2 enhances gemcitabine chemoresistance in pancreatic cancer in vivo.

Fig. 4

a Luminescence signal of xenografted tumors formed by indicated cells in mice after gemcitabine treatment. b The changes of tumor volume and luminescence with gemcitabine treatment in indicated cells (mean value is plotted). c Representative images of tumor mass removed from mice with xenografted tumors. d Tumor weight (mg) of the collected tumor mass removed from mice xenografted with indicated cancer cells (*P < 0.05). e Representative images of PROM2 and TUNEL immunostaining in indicated tumor tissues; the quantification of results is shown on the right panel (*P < 0.05), the PROM2 expression of vector group has been set as 1.